NEUROGENE INC (NGNE)
US64135M1053 - Common Stock
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Monday's session: top gainers and losers
What's going on in today's session
Let's have a look at the top gainers and losers in the middle of the day of today's session.
These stocks are gapping in today's session
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.
These stocks are moving in today's pre-market session
Stay updated with the stocks that are on the move in Monday's pre-market session.
Neurogene Announces Oversubscribed $200 Million Private Placement
Noteworthy Wednesday Option Activity: WING, NGNE, VICR
Commit To Purchase Neurogene At $25, Earn 16% Using Options
NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024
NGNE stock results show that Neurogene missed analyst estimates for earnings per share the second quarter of 2024.
NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Neurogene (NASDAQ:NGNE) just reported results for the second quarter of 2024.Ne...
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
Neurogene to Participate in BMO Genetic Medicines Summit
Neurogene Announces Addition to Russell 3000® Index
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Neurogene to Participate in Upcoming Conferences
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
Neurogene Becomes Oversold (NGNE)
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Neurogene (NASDAQ:NGNE) just reported results for the first quarter of 2024.Neu...
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024
NGNE stock results show that Neurogene beat analyst estimates for earnings per share the first quarter of 2024.
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene is Now Oversold (NGNE)
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
Neurogene to Participate in Upcoming Investor Conferences
Neurogene names Julie Jordan as chief medical officer (NASDAQ:NGNE)
Neurogene Inc announces the appointment of Julie Jordan as Chief Medical Officer, bringing over 20 years of industry and clinical expertise.
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
